Topiramate as an adjunctive treatment in patients with refractory status epilepticus: An observational cohort study

CNS Drugs

Volumn 26, Issue 9, 2012, Pages 761-772

  Hottinger, Annalena ^a   Sutter, Raoul ^b,c   Marsch, Stephan ^b   Rüegg, Stephan ^b  

^a UNIVERSITY OF BASEL   (Switzerland)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anaesthetics; Antiepileptic drugs; Epilepsy; Status epilepticus; Topiramate

Indexed keywords

TOPIRAMATE; VALPROIC ACID;

ADJUVANT THERAPY; ADULT; AGED; CLINICAL ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPILEPTIC STATE; FEMALE; HUMAN; HYPERAMMONEMIA; HYPERCHLOREMIC ACIDOSIS; INTENSIVE CARE UNIT; MALE; MEDICAL RECORD REVIEW; MORTALITY; PRIORITY JOURNAL; REVIEW;

ANESTHETICS; ANTICONVULSANTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FRUCTOSE; GASTROSTOMY; HUMANS; INTUBATION, GASTROINTESTINAL; MALE; MEDICAL RECORDS; MIDDLE AGED; RETROSPECTIVE STUDIES; STATUS EPILEPTICUS; TREATMENT OUTCOME;

EID: 84865275672     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.2165/11633090-000000000-00000     Document Type: Review

References (61)

1. Coeytaux A, Jallon P, Galobardes B, et al. Incidence of status epilepticus in French-speaking Switzerland (EPISTAR). Neurology 2000; 55 (5): 693-7
2. Knake S, Rosenow F, Vescovi M, et al. Incidence of status epilepticus in adults in Germany: a prospective, population-based study. Epilepsia 2001; 42 (6): 714-8
3. Ruegg S. Non-convulsive status epilepticus in adults: an overview. Swiss Arch Neurol Psychiatry 2008; 159 (2): 53-83
4. Cooper AD, Britton JW, Rabinstein AA. Functional and cognitive outcome in prolonged refractory status epilepti-cus. Arch Neurol 2009; 66 (12): 1505-9
5. Seif-Eddine H, Treiman DM. Problems and controversies in status epilepticus: a review and recommendations. Expert Rev Neurother 2011; 11 (12): 1747-58
6. Lowenstein DH, Alldredge BK. Status epilepticus. New Engl J Med 1998; 338 (14): 970-6
7. Mayer SA, Claassen J, Lokin J, et al. Refractory status epilepticus. Arch Neurol 2002; 59 (2): 205-10
8. Holtkamp M, Othman J, Buchheim K, et al. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2006; 76 (4): 534-9
9. Rossetti AO, Logroscino G, Bromfield EB. Refractory sta-tus epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005; 62 (11): 1698-702. Erratum in: Arch Neurol 2006; 63 (10): 1482
10. Novy J, Logroscino G, Rossetti AO. Refractory status epi-lepticus: a prospective observational study. Epilepsia 2010; 51 (2): 251-6
11. Abend NS, Dlugos DJ. Treatment of refractory status epi-lepticus: literature review and a proposed protocol. Pediatr Neurol 2008; 38 (6): 377-90
12. Holtkamp M. Treatment strategies for refractory status epilepticus. Curr Opin Crit Care 2011; 17 (2): 94-100
13. Rossetti AO, Lowenstein DH. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 2011; 10 (10); 922-30
14. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134 (10): 2802-18
15. Bausell R, Svoronos A, Lennihan L, et al. Recovery after severe refractory status epilepticus and 4 months of coma. Neurology 2011; 77 (15): 1494-5
16. Standley K, Abdulmassih R, Benbadis S. Good outcome is possible after months of refractory convulsive status epi-lepticus: lesson learned. Epilepsia 2012; 53 (1): e17-20
17. Shank RP, Maryanoff BE. Molecular pharmacodynamics, clinical therapeutics, and pharmacokinetics of topiramate. CNS Neurosci Ther 2008; 14 (2); 120-42
18. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic in-teractions of topiramate. Clin Pharmacokinet 2004; 43 (12): 763-80
19. Johannessen Landmark C, Patsalos PN. Drug interactions involving the new second-and third-line generation anti-epileptic drugs. Expert Rev Neurother 2010; 10 (1): 119-40
20. Lyseng-Williamson KA, Yang LPH. Topiramate: a review of its use in the treatment of epilepsy. Drugs 2007; 67 (15): 2231-56
21. Doose DR, Walker SA, Gisclon LG, et al. Single-dose pharmacokinetics and effect of food on the bioavailability of topiramate, a novel antiepileptic drug. J Clin Pharmacol 1996; 36 (10): 884-91
22. Reuber M, Evans J, Bamford M. Topiramate in drug-resistent complex partial status epilepticus. Eur J Neurol 2002; 9 (1): 111-2
23. Towne AR, Garnett LK, Waterhouse EJ, et al. The use of topiramate in refractory status epilepticus. Neurology 2003; 60 (2): 332-4
24. Bensalem MK, Fakhoury TA. Topiramate and status epilepti-cus: report of three cases. Epilepsy Behav 2003; 4 (6): 757-60
25. Kahriman M, Minecam D, Kutulay E, et al. Efficacy of to-piramate in children with refractory status epilepticus. Epilepsia 2003; 44 (10): 1353-6
26. Blumkin L, Lerman-Sagie T, Houri T, et al. Pediatric refractory partial status epilepticus responsive to topir-amate. J Child Neurol 2005; 20 (3): 239-41
27. Perry MS, Holt PJ, Sladky JT. Topiramate loading for refractory status epilepticus in children. Epilepsia 2006; 47 (6): 1070-1
28. Kroll-Seger J, Portilla P, Dulac O, et al. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics 2006; 37 (6): 325-9
29. Soler B, Godoy J, Mellado Talesnik P. Treatment of refrac-tory status epilepticus with topiramate: report of three cases [in Spanish]. Rev Med Chil 2009; 137 (7): 936-9
30. Bragatti JA, Torres CM, Netto CB, et al. Topiramate is ef-fective for status epilepticus and seizure control in neura-minidase deficiency. Arq Neuropsiquiatr 2011; 69 (3): 565-6
31. Akyildiz BN, Kumandas S. Treatment of pediatric refrac-tory status epilepticus with topiramate. Childs Nerv Syst 2011; 27 (9): 1425-30
32. Stojanova V, Rossetti AO. Oral topiramate as an add-on treatment for refractory status epilepticus. Acta Neurol Scand 2012; 125 (2): e7-11
33. Synowiec AS, Yandora KA, Yenugadhati V, et al. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res 2012; 98 (2-3): 232-7
34. Hirsch LJ, Brenner RP, Drislane FW, et al. The ACNS subcommittee on research terminology for continuous EEG monitoring: proposed standardized terminology for rhythmic and periodic EEG patterns encountered in critically ill patients. J Clin Neurophysiol 2005; 22 (2): 128-35
35. Hamer HM, Knake S, Schomburger U, et al. Valproate-induced hyperammonemic encephalopathy in the presence of topiramate. Neurology 2000; 54 (1): 230-2
36. Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40 (1): 120-2
37. Kellinghaus C, Stogbauer F. Treatment of status epilepticus in a large community hospital. Epilepsy Behav 2012; 23: 235-40
38. Young GB, Jordan KG, Doig GS. An assessment of non-convulsive seizures in the intensive care unit using continuous EEG monitoring: an investigation of variables associated with mortality. Neurology 1996; 47 (1): 83-9
39. Sutter R, Fuhr P, Grize L, et al. Continuous video-EEG monitoring increases detection rate of nonconvulsive status epilepticus in the ICU. Epilepsia 2011; 52 (3): 453-7
40. Rudin D, Grize L, Schindler C, et al. High prevalence of nonconvulsive and subtle status epilepticus in an ICU of a tertiary care center: a three-year observational cohort study. Epilepsy Res 2011; 96 (2-3): 140-50
41. Claassen J, Lokin J, Fitzsimmons BF, et al. Predictors of functional disability and mortality after status epilepticus. Neurology 2002; 58 (1): 139-42
42. Legriel S, Azoulay E, Resche-Rigon M, et al. Functional outcome after convulsive status epilepticus. Crit Care Med 2010; 38 (12): 2295-303
43. Drislane FW, Blum AS, Lopez MR, et al. Duration of refractory status epilepticus and outcome: loss of prognostic utility after several hours. Epilepsia 2009; 50 (6): 1566-71
44. Delanty N, French JA, Labar DR, et al. Status epilepticus arising de novo in hospitalized patients: an analysis of 41 patients. Seizure 2001; 10 (2): 116-9
45. Boggs JG. Mortality associated with status epilepticus. Epilepsy Curr 2004; 4 (1): 25-7
46. Cereda C, Berger MM, Rossetti AO. Bowel ischemia: a rare complication of thiopental treatment for status epilepticus. Neurocrit Care 2009; 10 (3): 355-8
47. Iyer VN, Hoel R, Rabinstein AA. Propofol infusion syndrome in patients with refractory status epilepticus: an 11-year clinical experience. Crit Care Med 2009; 37 (12): 3024-30
48. Roberts RJ, Barletta JF, Fong JJ, et al. Incidence of pro-pofol-related infusion syndrome in critically ill adults: a prospective, multicenter study. Crit Care 2009; 13 (5): R169
49. Wong JM. Propofol infusion syndrome. Am J Ther 2010; 17 (5): 487-91
50. Rossetti AO, Hurwitz S, Logroscino G, et al. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry 2006; 77 (5): 611-5
51. Rossetti AO, Logroscino G, Liaudet L, et al. Status epi-lepticus: an independent outcome predictor after cerebral anoxia. Neurology 2007; 69 (3): 255-60
52. Wasterlain CG, Chen JWY. Mechanistic and pharmacolo-gic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia 2008; 49 Suppl. 9: S63-73
53. Rogawski MA. Revisiting AMPA receptors as an anti-epileptic drug target. Epilepsy Curr 2011; 11 (2): 53-63
54. Niebauer M, Gruenthal M. Topiramate reduces neuronal injury after experimental status epilepticus. Brain Res 1999; 837 (1-2): 263-9
55. Rigoulot MA, Koning E, Ferrandon A, et al. Neuroprotective properties of topiramate in the lithium-pilocarpine model of epilepsy. J Pharmacol Exp Ther 2004; 308 (2): 787-95
56. Fisher A, Wang X, Cock HR, et al. Synergism between to-piramate and budipine in refractory status epilepticus in the rat. Epilepsia 2004; 45 (11): 1300-7
57. Kudin AP, Debska-Vielhaber G, Vielhaber S, et al. The mechanism of neuroprotection by topiramate in an animal model of epilepsy. Epilepsia 2004; 45 (12): 1478-87
58. François J, Koning E, Ferrandon A, et al. The combination of topiramate and diazepam is partially neuroprotective in the hippocampus but not antiepileptogenic in the lithium-pilocarpine model of temporal lobe epilepsy. Epilepsy Res 2006; 72 (2-3): 147-63
59. Shatskikh T, Zhao Q, Zhou JL, et al. Effect of topiramate on cognitive function and single units from hippocampal place cells following status epilepticus. Epilepsy Behav 2009; 14 (1): 40-7
60. Fakhoury T, Murray L, Seger D, et al. Topiramate over-dose: clinical and laboratory features. Epilepsy Behav 2002; 3 (2): 185-9
61. Brandt C, Elsner H, Furatsch N, et al. Topiramate overdose: a case report of a patient with extremely high topiramate serum concentrations and nonconvulsive status epilepticus. Epilepsia 2010; 51 (6): 1090-3